Navigation Links
Vasogen Announces 2007 Year-End Results
Date:1/16/2008

ing costs (154) (2,495) (408) (3,057)

Loss on extinguishment of

senior convertible notes

payable (1,754) (4,995) - (6,749)

Investment income 1,310 1,971 2,274 13,325

Change in fair value of

embedded derivatives 829 - - 829

-------------------------------------------------------------------------

Loss and comprehensive loss

for the period (28,777) (66,360) (93,048) (374,340)

Deficit, beginning

of period:

As originally reported (351,374) (284,719) (187,665) (1,510)

Impact of change in

accounting for stock-

based compensation - - (4,006) (4,006)

Impact of change in

accounting for financial

instruments on

December 1, 2006 (1,632) - - (1,632)

-----------------------------------------------------------

As revised (353,006) (284,719) (191,671)

Charge for acceleration

payments on equity

component of senior

convertible notes payable - (295) - (295)

-------------------------------------------------------------------------

Deficit, end of period $(381,783) $(351,374) $(284,719) $(381,783)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and diluted loss per

common share $ (1.46) $ (7.05) $ (11.65)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

VASOGEN INC.

(A DEVELOPMENT STAGE COMPANY)

Consolidated Statements o
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 InspireMD, ... in embolic protection stents, announced that Alan Milinazzo ... Craig Shore , the Company,s Chief Financial ... Conference on Thursday May 30, 2013 at The Pfister Hotel, ... The format of the conference includes a number ...
(Date:5/24/2013)... 24, 2013 This market report ... kinase profiling carried out in May 2013. The ... breakdown of the responses for each question, its ... It also highlights some interesting differences, particularly between ... bottom-up models were developed to estimate the in ...
(Date:5/24/2013)... OK (PRWEB) May 24, 2013 The ... casualties. And following its ravage, the mayor of Moore, one ... for new houses, said a report from cnn.com. Reaching out ... tornado victims complimentary Molderizer and Safe Shield to counter the ... the report published on May 22, 2013, caused 24 deaths, ...
(Date:5/24/2013)... Quincy Bioscience, a leading research company ... proteins to support healthy living, is pleased to ... apoaequorin in Food and Chemical Toxicology ... Industrial Biological Research Association. , The objective ... effects, if any, of apoaequorin, in rats following ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
... IRVINE, Calif. , April 26 ChromaDex ... company which provides novel and innovative ingredients to the ... the launch of pTeroPure™ pterostilbene(tero-STILL-bean). This exciting new product ... worldwide license to all patent rights of pterostilbene from ...
... , HOERSHOLM, Denmark and SAN DIEGO ... a clinical-stage biopharmaceutical company focused on the discovery and ... advanced into drug development a discovery research candidate directed ... new target for the treatment of high cholesterol. Using ...
... Asymchem Laboratories is proud to announce and welcome Dr. Guojie ... Director of Chemical Development, and Dr. Xiaojun Huang as Senior ... , ... 2010 .  He brings extensive scientific and managerial experience in pharmaceutical formulations ...
Cached Biology Technology:ChromaDex Launches pTeroPure Pterostilbene 2ChromaDex Launches pTeroPure Pterostilbene 3ChromaDex Launches pTeroPure Pterostilbene 4ChromaDex Launches pTeroPure Pterostilbene 5Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 3Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 4Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 5Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang 2
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... 23, 2013) A new report from the Institute ... pupils engage in at least 60 minutes of vigorous ... No more than half of American youth meet current ... or moderate intensity physical activity daily, according to the ... are in school for nearly half of their waking ...
(Date:5/23/2013)... the interplay of brain chemicals which help us pay ... BBSRC. , By changing the way neurons respond ... these changes can affect the strength of a neuronal ... response. , Lead author Alex Thiele, Professor ... you can make yourself better heard by speaking louder ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
... aboard the RMS Titanic, which is contributing to its ... to the exterior of ships and underwater metal structures ... their findings in the latest issue of the ... on 8 December, isolated the micro-organisms from a ,rusticle, ...
... new book, Illinois Birds: A Century of Change, literally took ... in Illinois was conducted from 1906-1909. It was repeated from ... surveys. When the 100-year anniversary of that first survey was ... Brawn seized the window of opportunity to do it again ...
... ,Cleveland - Scientists from South Korea, the United ... Korea and published research describing a new horned dinosaur. ... lived about 103 million years ago during the late ... ceratopsian dinosaur from the Korean peninsula. The partial ...
Cached Biology News:New microscopic life aboard the RMS Titanic 2New book on 100 years of Illinois birds 2New book on 100 years of Illinois birds 3New book on 100 years of Illinois birds 4Scientists announce discovery of first horned dinosaur from South Korea 2
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Feline IL-2, CF...
... Fernandez and G. Butcher (1998). • The ... much research in the immunology area. There ... MHC proteins and in their function as ... faced with the prospect of tackling biochemical ...
Biology Products: